For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
The Minister of Health is seeking assurance through an independent review about how well positioned the NBSP is for successful delivery, what changes might be required and what the Ministry of Health can learn to support the design and roll out of further national initiatives.
The Health Quality and Safety Commission (HQSC) will provide expert project management and secretariat support to the review team to ensure timely delivery of the findings.
Professor Gregor Coster will lead the review team that includes Dr William Rainger, Professor Graeme Young and Dr Mary Seddon.
Additional reviewer(s) with particular areas of expertise can be appointed to support the Lead reviewer.
The review team will also include input from a Public Health Medicine Specialist to provide expertise on population health systems and the impacts of these systems on the quality and safety of the roll out with a focus on future improvements.